|
|
|
| Clinical effect of Amifostine combined with Gemcitabine and Cisplatin in the treatment of advanced breast cancer |
| MU Ya-nan |
| Department of Pathology,Shihezi University School of Medicine,Xinjiang Uygur Autonomous Region,Shihezi 832003,China |
|
|
|
|
Abstract Objective To investigate the clinical effect of Amifostine combined with Gemcitabine and Cisplatin in the treatment of advanced breast cancer.Methods A total of 140 patients with advanced breast cancer treated in the First Affiliated Hospital,School of Medicine,Shihezi University from May 2014 to June 2016 were selected as the study subjects.They were divided into experimental group and reference group by random number table method,with 70 cases in each group.The control group was treated with Gemcitabine and Cisplatin,and the experimental group was treated with Amifostine.The total effective rate,the total incidence of adverse reactions,the survival time and the 1-year and 2-year expected survival rates of the two groups were compared,and the pain of the two groups before and after treatment was observed.Results The total effective rate of the experimental group (71.43%) was higher than that of the reference group (58.57%),and the difference was statistically significant (P<0.05).The total incidence of adverse reactions in the experimental group (14.29%) was lower than that in the reference group (25.71%),and the difference was statistically significant (P<0.05).The survival time of the experimental group was longer than that of the reference group,and the 1-year and 2-year expected overall survival rate was higher than that of the reference group,the differences were statistically significant (P<0.05).After treatment,the pain score of the experimental group was lower than that of the reference group,the difference was statistically significant (P<0.05).The pain scores of the two groups after treatment was lower than those before treatment,the differences were statistically significant (P<0.05).Conclusion For patients with advanced breast cancer,Amifostine combined with Gemcitabine and Cisplatin can improve the therapeutic effect and reduce the total incidence of adverse reactions,which is worthy of promotion and application.
|
|
|
|
|
|
| [1] |
解国清，邵艳，李雷，等.替吉奥联合奥沙利铂以及吉西他滨联合顺铂治疗晚期三阴性乳腺癌的临床效果比较[J].中国综合临床，2019，35（3）：259-262.
|
| [2] |
徐蕾，朱晓莺，吴玲姣，等.吉西他滨联合洛铂与联合顺铂方案治疗术后辅助化疗失败的卵巢癌患者的疗效对比[J].现代肿瘤医学，2018，26（21）：3481-3484.
|
| [3] |
乔亚梅，董新芬.超声对乳腺癌患者术前分期的诊断价值[J].实用癌症杂志，2017，32（10）：1638-1640.
|
| [4] |
莫淑芬，钟海鸣，许靖靖，等.吉西他滨联合顺铂与紫杉醇联合顺铂一线治疗晚期三阴性乳腺癌的效果比较[J].中国当代医药，2018，25（35）：44-46，49.
|
| [5] |
何江涛，王伟，钟海鸣，等.长春瑞滨联合顺铂对比多西他赛联合顺铂一线治疗晚期三阴性乳腺癌的临床研究[J].临床医学工程，2018，25（12）：1613-1614.
|
| [6] |
崔文秀，郝吉庆.吉西他滨不同给药方式联合顺铂治疗晚期乳腺癌的临床疗效及安全性[J].现代肿瘤医学，2018，26（13）：2048-2050.
|
| [7] |
姚艺玮，王勇，何义富，等.氨磷汀对恶性肿瘤化疗患者肝脏保护作用的临床观察[J].中国临床保健杂志，2018，21（3）：302-304.
|
| [8] |
张蕾，薛永飞，冀叶，等.氨磷汀联合多西他赛和卡铂治疗卵巢癌的临床研究[J].现代药物与临床，2018，33（3）：621-624.
|
| [9] |
张凌捷，葛睿，李翔，等.长春瑞滨或吉西他滨+顺铂治疗耐多药性晚期三阴乳腺癌行的疗效比较[J].医学临床研究，2018，35（6）：1213-1215.
|
| [10] |
王洪涛，黄远丽，董超，等.吉西他滨或长春瑞滨联合顺铂治疗转移性三阴性乳腺癌的疗效比较[J].现代中西医结合杂志，2017，26（2）：164-166.
|
| [11] |
胡雪，李玮，孟永鹏.曲妥珠单抗联合长春瑞滨或吉西他滨对人类表皮生长因子受体2阳性乳腺癌患者的临床观察[J].药物评价研究，2019，42（3）：505-508.
|
| [12] |
解华，刘宏杰，王玮.沙利度胺联合GP方案治疗晚期三阴性乳腺癌疗效观察[J].蚌埠医学院学报，2017，42（7）：878-880，884.
|
| [13] |
毛静瑜，曾赟，沈政洁，等.扶正化瘤方联合吉西他滨和顺铂治疗转移性三阴性乳腺癌的临床观察[J].中国肿瘤临床与康复，2017，24（8）：897-900.
|
| [14] |
左一凡，高立伟，武素芳，等.吉西他滨联合顺铂调控mTOR/S6K1/NF-κB信号治疗乳腺癌的机制研究[J].实用癌症杂志，2019，34（1）：26-29.
|
| [15] |
吴金朋.吉西他滨联合顺铂对Ⅲ期乳腺癌术后患者MMP-9及雌激素水平的影响[J].医学临床研究，2017，34（3）：563-564.
|
|
|
|
